Guardant Health Reports Results of Blood-Only Liquid Biopsy Test Predicting Risk of Colorectal Cancer Recurrence

 Guardant Health Reports Results of Blood-Only Liquid Biopsy Test Predicting Risk of Colorectal Cancer Recurrence

Shots:

  • The study evaluates the effectiveness of the Guardant Reveal liquid biopsy test to detect MRD in patients with stage I-IV colorectal cancer after curative intent therapy
  • The blood samples were taken from intent population within 1mos. after treatment completion and in the subset of patients with clinical follow-up of 1yr, all patients with detectable ctDNA recurred. Guardant Reveal test sensitivity & specificity (55.6% & 100%) respectively for this single timepoint
  • The new test showed 91% sensitivity in detecting ctDNA by examining both genomic & epigenomic alterations of longitudinal surveillance samples

Click here to­ read full press release/ article | Ref: Businesswire | Image: Guardant

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post